Maryland Psychiatric Research Center
Catonsville, Maryland, 21228, United States
NCT Number: NCT01967667
Low levels of antioxidant molecules such as glutathione have been found in people with a diagnosis of schizophrenia. However, oral glutathione is not well absorbed because the compound is mostly broken down in the gastrointestinal system. Liposomes are tiny droplets of oil particles that encapsulate and protect the glutathione. In this study we will evaluate a liposomal formulation of glutathione for tolerability and to examine if this formulation serves the function of increasing glutathione in the brain and body.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Catonsville, Maryland, 21228, United States
Additional information about this dietary supplement:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Escalating dose steps
Other names: ReadiSorb glutathione
escalating dose steps
Other names: Readisorb solution without glutathione
Time frame: Baseline and 3 weeks
Change of glutathione levels from baseline to following 3 weeks of treatment.
Time frame: baseline and 3 weeks
blood levels of lipid peroxidation
Time frame: baseline and 3 weeks
Blood levels of cytokines as biomarkers of inflammation
Time frame: Baseline and 3 weeks
Change in brief psychiatric rating scale scores from baseline to end of treatment phase and end of placebo phase.
Time frame: Baseline and 3 weeks
side-effects checklist
University of Maryland, Baltimore
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05838573
Cognition Disorders, Cognitive Dysfunction
Changsha, Hunan, China
View Trial DetailsNCT05304767
Mental Disorders, Schizophrenia
Phoenix, Arizona, United States
View Trial DetailsNCT00004571
Mental Disorders, Normal Physiology
Bethesda, Maryland, United States
View Trial DetailsNCT05808244
Mental Disorders, Psychosis
Kowloon, Hong Kong
View Trial Details